There's a huge amount of work being done these days on T cells in developing new immuno-oncology drugs for cancer. And researchers at Tübingen University say they have developed a new tracking technology that will allow those working in the field to understand better how these new therapies are working. Overcoming earlier technology barriers that could damage the T cells, the Tübingen team says that they developed an antibody with a weak radioactive element that attached to the outer membrane of the attack cells. The radiation signal was then tracked with a PET device. Release